GlobalData Plc

The European revision knee replacement market, which covers 21 countries, is set to rise modestly from around $259m in 2016 to just over $304m by 2023, representing a compound annual growth rate of 2.3%, according to GlobalData, a recognized leader in providing business information and analytics.

The company’s latest report states that knee reconstruction is a fully mature market that has experienced no major innovation over the last decade, and only incremental improvements. As health executives are scrutinizing purchases and using multiple channels to procure orthopedic devices at highly competitive prices, profit margins have been negatively affected. As such, revenue growth is dwindling in the global large joint reconstruction space.

Tobe Madu, MSc, Healthcare Analyst for GlobalData, explains: “Since revision knee replacement is highly correlated with total knee arthroplasty (TKA), there are multiple paths that the market could take as this space develops, each of which are dependent on the market dynamics of TKA. On one hand, investments could be made into expensive capital equipment, such as robots, which will result in consistent, reproducible implant replacement, less soft tissue damage, and less rehabilitation, leading to lower revision surgery cases.

“On the other hand, the use of inexpensive generic implants could decrease the direct cost of surgery but increase the rate of revisions. The rate of advancement in technologies such as 3D printing and telerobotics will highly influence how these two alternatives scenarios play out to affect the rate of revision knee procedures.”

The procedure volume for revision knee replacements is expected to grow proportionally with that of primary knee replacements due to the demographics of an aging population, a trend towards early surgical intervention in younger patients, and further improvements in insurance coverage in emerging countries.

Madu concludes: “In the years to come, launching and marketing a comprehensive large joint portfolio with a clear value proposition will remain critical to companies’ success as they jostle for market position. A long-term foothold within the global knee market will predicate companies’ success in revision knee replacement, and given the heightened competitive pressures and shrinking reimbursement in this space, GlobalData expects the average selling price for primary revision knee replacement implants to decline in all 21 markets.”

Information based on GlobalData’s report: MediPoint: Revision Knee Arthroplasty – Europe Analysis and Market Forecasts.

Related Intelligence

Want more Insight like this?

Our interactive subscription platform has the most comprehensive data and analysis in your industry.

Request a Demo

Related Consulting

How can we help your business?

Our consultants are skilled in every specialist market niche to deliver solutions specifically designed for your individual requirements.

Request a Callback

    Press Release Healthcare

    Late-stage CKD-induced comorbidity therapeutics market to reach $10.5bn by 2026

    Sales for chronic kidney disease (CKD)-induced hyperparathyroidism (HPT), hyperphosphatemia (HP), and hyperkalemia (HK) therapeutics were estimated to be $4.2bn across the seven major markets (7MM*) in 2016. This is expected to grow to $10.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 9.5%, according to GlobalData, a leading data and analytics company.

    Press Release Healthcare

    Majority of oncology clinical trials in China failed to meet enrolment targets

    The majority of oncology clinical trials in China that had a start date between 1 January 2012 and 31 December 2017 failed to meet the planned enrolment targets, according to GlobalData, a leading data and analytics company. The company identified and analyzed enrollment efficiencies of 324 clinical trials during the period and found that on...

    Press Release Healthcare

    Need for supportive care in oncology will increase during the next decade

    The need for effective supportive care in oncology will increase in the next decade as patients continue to live longer and cancer progresses to become more like a chronic disease. This includes the need for chemotherapy-related conditions, as chemotherapy will remain the backbone of cancer therapy for the foreseeable future, observes GlobalData, a leading data and analytics company.

    Press Release Healthcare

    World Cancer Day: What will 2018 mean for cancer research and treatment?

    The theme of this year’s World Cancer Day held on 4th February of “We can. I can.” aimed to reinforce the public message that all individuals and groups can play their part in reducing the global burden of cancer. Indeed in recent years many events have involved collaborations between traditional drug developers, cancer treatment professionals and those of varying disciplines. Examples include the IBM Watson supercomputer which is helping physicians make treatment decisions and the development of other databases such as ASCO’s CancerLinQ which assists oncologists in monitoring and analyzing patient data.

    Press Release Healthcare

    Melanoma sales are projected to rise to $5.5bn in 2026

    The value of the melanoma market was estimated to be $3.3bn across the seven major markets (7MM*) in 2016. This is expected to grow to $5.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 5.3%, according to GlobalData, a leading data and analytics company.

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we’re very happy to help.

Emailpr@globaldata.com
PhoneEMEA: +44 207 832 4399
PhoneAPAC: +91 40 6616 6809
Onlinecontact online

56% of #consumers are concerned about the impact of diet. Join us for more insight @incosmetics #cosmetics #trends… https://t.co/wJOJOqYIJF